speb/financial-data huggingface dataset:
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 1664305000.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 385224000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 2424295000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1397331000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 2214237000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 250648000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 89129225.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 2.84
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 93652000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 994895000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 1020566000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 93652000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 7293464000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 535909000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 1655630000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 6611459000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 2029979000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 2029979000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 3751797000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 12030000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 100206000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 100206000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 89129225.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 2.84
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 253127000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — EBIT: 397780000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — EBITDA: 497986000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 26066000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 5675232000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 768665000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 57362000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 57362000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 3174660000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 10536492000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 250648000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 1213049000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 1213049000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 12150000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: 1000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 2248133000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income: 253127000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 253127000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 253127000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 253127000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 253127000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 253127000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -57362000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -57362000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 5675232000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 7267398000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 494143000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 497986000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 253127000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Operating Income: 383441000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 2424295000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 93652030.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 201996000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 26933000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 7199812000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 201199000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 14339000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 92504000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 5139323000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 25671000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Payables: 1422250000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 340418000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 1655630000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 100206000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 93652030.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 7293464000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 7267398000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 89125000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.26
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 12764604000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 8506513000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 3243028000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 7293465000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 2040854000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 5471139000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 6153145000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 1719342000.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 24919000.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 2859662000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 412583000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 2104470000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 90625483.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 2.59
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 1355587000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 100152000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 100152000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 90625483.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 2.59
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 234720000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — EBIT: 373824000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — EBITDA: 473976000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 748883000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 62223000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 62223000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income: 234720000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 234720000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 234720000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 234720000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 234720000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 234720000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -62223000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -62223000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 473976000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 234720000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Income: 336300000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 2104470000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 37524000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 101910000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 311601000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1355587000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 100152000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 79706000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.26
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 1768170000.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — +Operating Expense: 1714663000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 515138000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — +Total Revenue: 8868710000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 2379475000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 1204336000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1204336000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 2158662000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 2158662000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 374814000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 374814000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 91379609.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 3.58
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 413991000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -1305582000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 93652000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 93652000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 458770000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 458770000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 495229000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 495229000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -35461000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -664772000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -231001000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 25380000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Payable: 65168000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Prepaid Assets: -8311000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -126326000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -939862000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 44779000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock: 93652000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 93652000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 7858088000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 7858088000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 476207000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 1216417000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 1216417000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 5840453000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1566646000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Assets: 6380110000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 6380110000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt: 1934079000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 1934079000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 1934079000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 1934079000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 3529763000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 3529763000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 9246000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 9246000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation: 399193000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 399193000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 399193000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 101309000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 399193000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 101309000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 91379609.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 3.58
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 1019891000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 327139000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — EBIT: 1397132000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — EBIT: 323435000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — EBITDA: 1796325000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — EBITDA: 424744000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — End Cash Position: 458770000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 760345000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -713345000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 27960000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 27960000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 6528584000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 6528584000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Gross Profit: 3028257000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 812829000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense: 230756000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 52767000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 230756000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 52767000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -221117000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 7999000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Inventory: 3512064000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 3512064000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 11508568000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 11508568000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -1307803000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 374814000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 374814000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 476207000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 884236000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 1716401000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 1716401000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 1716401000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 1716401000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 623186000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -343520000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 11986000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 11986000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 1000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 1000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 476207000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Debt: 3191710000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 3191710000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Net Income: 1019891000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income: 327139000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 1019891000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 327139000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 1019891000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 327139000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1019891000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 327139000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1019891000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 327139000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 1166377000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 1019891000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 327139000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Net Interest Income: -230756000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -52767000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -41000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 540716000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 279666000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -230756000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -52767000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: -10179000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Net PPE: 6528584000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 6528584000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -1305582000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: 261050000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 7830128000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 7830128000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 508153000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 508153000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 1796325000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 424744000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Normalized Income: 1019891000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 327139000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 592237000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Operating Income: 1313594000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Income: 297691000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Operating Revenue: 8868710000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 2379475000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 93652030.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 93652030.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 214155000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 214155000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 58298000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 58298000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 7764436000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 7764436000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 214456000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 312924000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 312924000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 83538000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 25744000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 435914000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 119157000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Properties: 5312167000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 5312167000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 36459000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 36459000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Payables: 1210485000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Payables: 1210485000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Pension And Employee Benefit Expense: -1470000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Pretax Income: 1166376000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 270668000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -41000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -1305582000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 5840453000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 1566646000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 399193000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 101309000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -343520000.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 0.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Share Issued: 93652030.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 93652030.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Short Term Debt Issuance: 261050000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Special Income Charges: 0.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 7858088000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 7858088000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 7830128000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 7830128000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Tax Provision: 286397000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 61023000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.25
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.23
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 0.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 0.00
SMSPHARMA.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -241000000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Assets: 13624392000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 13624392000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 9574489000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 9574489000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Debt: 3650480000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 3650480000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 7858089000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 7858089000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Total Expenses: 7555116000.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 2081784000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 5766303000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 5766303000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 7244282000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 7244282000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2236540000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2236540000.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 6149000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 6149000.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 0.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
SMSPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
SMSPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
SMSPHARMA.NS balance_sheet (annual, 2026-03-31) — Working Capital: 2850347000.00
SMSPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 2850347000.00
SMT.L cash_flow (annual, 2022-03-31) — Common Stock Issuance: 518246000.00
SMT.L cash_flow (annual, 2022-03-31) — Issuance Of Capital Stock: 518246000.00
SMT.L balance_sheet (annual, 2022-03-31) — Other Payable: 23814000.00
SMT.L income_statement (annual, 2023-03-31) — +Operating Expense: 5861000.00
SMT.L income_statement (annual, 2023-03-31) — +Total Revenue: -2912533000.00
SMT.L balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 947494000.00
SMT.L income_statement (annual, 2023-03-31) — Basic Average Shares: 1428245353.00
SMT.L income_statement (annual, 2023-03-31) — Basic EPS: -2.05
SMT.L cash_flow (annual, 2023-03-31) — Beginning Cash Position: 229962000.00
SMT.L balance_sheet (annual, 2023-03-31) — Capital Stock: 70381000.00
SMT.L balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 184945000.00
SMT.L balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Federal Funds Sold: 184945000.00
SMT.L cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -52585000.00
SMT.L cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: -2449000.00
SMT.L cash_flow (annual, 2023-03-31) — Change In Working Capital: -2449000.00
SMT.L cash_flow (annual, 2023-03-31) — Changes In Cash: -65398000.00
SMT.L balance_sheet (annual, 2023-03-31) — Common Stock: 70381000.00
SMT.L cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: -52585000.00
SMT.L balance_sheet (annual, 2023-03-31) — Common Stock Equity: 11498000000.00
SMT.L cash_flow (annual, 2023-03-31) — Common Stock Issuance: 0.00
SMT.L cash_flow (annual, 2023-03-31) — Common Stock Payments: -283213000.00
SMT.L income_statement (annual, 2023-03-31) — Diluted Average Shares: 1428245353.00
SMT.L income_statement (annual, 2023-03-31) — Diluted EPS: -2.05
SMT.L income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: -2922138000.00
SMT.L cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: 20381000.00
SMT.L cash_flow (annual, 2023-03-31) — End Cash Position: 184945000.00
SMT.L balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 13149592000.00
SMT.L cash_flow (annual, 2023-03-31) — Financing Cash Flow: -732948000.00
SMT.L cash_flow (annual, 2023-03-31) — Free Cash Flow: -63477000.00
SMT.L cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: 2790255000.00
SMT.L income_statement (annual, 2023-03-31) — Gain On Sale Of Security: 457811000.00
SMT.L income_statement (annual, 2023-03-31) — General And Administrative Expense: 4629000.00
SMT.L income_statement (annual, 2023-03-31) — Interest Expense: 66612000.00
SMT.L income_statement (annual, 2023-03-31) — Interest Income: 10457000.00
SMT.L cash_flow (annual, 2023-03-31) — Interest Paid Cfo: -66322000.00
SMT.L balance_sheet (annual, 2023-03-31) — Invested Capital: 13321294000.00
SMT.L cash_flow (annual, 2023-03-31) — Investing Cash Flow: 731027000.00
SMT.L balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 13149592000.00
SMT.L balance_sheet (annual, 2023-03-31) — Investments And Advances: 13149592000.00
SMT.L cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 0.00
SMT.L cash_flow (annual, 2023-03-31) — Issuance Of Debt: 1591000000.00
SMT.L balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 1823294000.00
SMT.L cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 1591000000.00
SMT.L cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -1988150000.00
SMT.L cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: -283213000.00
SMT.L balance_sheet (annual, 2023-03-31) — Net Debt: 1638349000.00
SMT.L cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 68748000.00
SMT.L income_statement (annual, 2023-03-31) — Net Income: -2922138000.00
SMT.L income_statement (annual, 2023-03-31) — Net Income Common Stockholders: -2922138000.00
SMT.L income_statement (annual, 2023-03-31) — Net Income Continuous Operations: -2922138000.00
SMT.L income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: -2922138000.00
SMT.L income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: -2922138000.00
SMT.L cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: -2918394000.00
SMT.L income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: -2922138000.00
SMT.L income_statement (annual, 2023-03-31) — Net Interest Income: -56155000.00
SMT.L cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: 731027000.00
SMT.L cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -397150000.00
SMT.L cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -397150000.00
SMT.L cash_flow (annual, 2023-03-31) — Net Other Financing Charges: 0.00
SMT.L balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 11498000000.00
SMT.L income_statement (annual, 2023-03-31) — Normalized Income: -2922138000.00
SMT.L cash_flow (annual, 2023-03-31) — Operating Cash Flow: -63477000.00
SMT.L income_statement (annual, 2023-03-31) — Operating Revenue: -2912533000.00
SMT.L balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 1407618528.00
SMT.L cash_flow (annual, 2023-03-31) — Other Non Cash Items: 66612000.00
SMT.L balance_sheet (annual, 2023-03-31) — Payables: 22055000.00
SMT.L income_statement (annual, 2023-03-31) — Pretax Income: -2918394000.00
SMT.L cash_flow (annual, 2023-03-31) — Purchase Of Investment: -868191000.00
SMT.L balance_sheet (annual, 2023-03-31) — Receivables: 12037000.00
SMT.L cash_flow (annual, 2023-03-31) — Repayment Of Debt: -1988150000.00
SMT.L cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -283213000.00
SMT.L cash_flow (annual, 2023-03-31) — Sale Of Investment: 1599218000.00
SMT.L income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 1232000.00
SMT.L income_statement (annual, 2023-03-31) — Selling General And Administration: 5861000.00
SMT.L balance_sheet (annual, 2023-03-31) — Share Issued: 1484780880.00
SMT.L balance_sheet (annual, 2023-03-31) — Stockholders Equity: 11498000000.00
SMT.L balance_sheet (annual, 2023-03-31) — Tangible Book Value: 11498000000.00
SMT.L income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 0.00
SMT.L income_statement (annual, 2023-03-31) — Tax Provision: 3744000.00
SMT.L income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.19
SMT.L cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -1927000.00
SMT.L balance_sheet (annual, 2023-03-31) — Total Assets: 13346574000.00
SMT.L balance_sheet (annual, 2023-03-31) — Total Capitalization: 13321294000.00
SMT.L balance_sheet (annual, 2023-03-31) — Total Debt: 1823294000.00
SMT.L balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 11498000000.00
SMT.L balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 1848574000.00
SMT.L balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 77162352.00
SMT.L income_statement (annual, 2024-03-31) — +Operating Expense: 5634000.00
SMT.L income_statement (annual, 2024-03-31) — +Total Revenue: 1377354000.00
SMT.L balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 947494000.00
SMT.L income_statement (annual, 2024-03-31) — Basic Average Shares: 1404228553.00
SMT.L income_statement (annual, 2024-03-31) — Basic EPS: 0.97
SMT.L cash_flow (annual, 2024-03-31) — Beginning Cash Position: 184945000.00
SMT.L balance_sheet (annual, 2024-03-31) — Capital Stock: 69293000.00
SMT.L balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 123762000.00
SMT.L balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Federal Funds Sold: 123762000.00
SMT.L cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -57659000.00
SMT.L cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -4344000.00
SMT.L cash_flow (annual, 2024-03-31) — Change In Working Capital: -4344000.00
SMT.L cash_flow (annual, 2024-03-31) — Changes In Cash: -58021000.00
SMT.L balance_sheet (annual, 2024-03-31) — Common Stock: 69293000.00
SMT.L cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -57659000.00
SMT.L balance_sheet (annual, 2024-03-31) — Common Stock Equity: 12629814000.00
SMT.L cash_flow (annual, 2024-03-31) — Common Stock Payments: -122056000.00
SMT.L income_statement (annual, 2024-03-31) — Diluted Average Shares: 1404228553.00
SMT.L income_statement (annual, 2024-03-31) — Diluted EPS: 0.97
SMT.L income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 1365963000.00
SMT.L cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: -3162000.00
SMT.L cash_flow (annual, 2024-03-31) — End Cash Position: 123762000.00
SMT.L balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 14118531000.00
SMT.L cash_flow (annual, 2024-03-31) — Financing Cash Flow: -332835000.00
SMT.L cash_flow (annual, 2024-03-31) — Free Cash Flow: -62390000.00
SMT.L cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -1405658000.00
SMT.L income_statement (annual, 2024-03-31) — Gain On Sale Of Security: 359702000.00
SMT.L income_statement (annual, 2024-03-31) — General And Administrative Expense: 4539000.00
SMT.L income_statement (annual, 2024-03-31) — Interest Expense: 54981000.00
SMT.L income_statement (annual, 2024-03-31) — Interest Income: 11594000.00
SMT.L cash_flow (annual, 2024-03-31) — Interest Paid Cfo: -55193000.00
SMT.L balance_sheet (annual, 2024-03-31) — Invested Capital: 14274270000.00
SMT.L cash_flow (annual, 2024-03-31) — Investing Cash Flow: 337204000.00
SMT.L balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 14118531000.00
SMT.L balance_sheet (annual, 2024-03-31) — Investments And Advances: 14118531000.00
SMT.L cash_flow (annual, 2024-03-31) — Issuance Of Debt: 504505000.00
SMT.L balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 1644456000.00
SMT.L cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 504505000.00
SMT.L cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -657625000.00
SMT.L cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -122056000.00
SMT.L balance_sheet (annual, 2024-03-31) — Net Debt: 1520694000.00
SMT.L cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -22211000.00
SMT.L income_statement (annual, 2024-03-31) — Net Income: 1365963000.00
SMT.L income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 1365963000.00
SMT.L income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 1365963000.00
SMT.L income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 1365963000.00
SMT.L income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 1365963000.00
SMT.L cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 1371720000.00
SMT.L income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 1365963000.00
SMT.L income_statement (annual, 2024-03-31) — Net Interest Income: -43387000.00
SMT.L cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 337204000.00
SMT.L cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -153120000.00
SMT.L cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -153120000.00
SMT.L cash_flow (annual, 2024-03-31) — Net Other Financing Charges: 0.00
SMT.L balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 12629814000.00
SMT.L income_statement (annual, 2024-03-31) — Normalized Income: 1365963000.00
SMT.L cash_flow (annual, 2024-03-31) — Operating Cash Flow: -62390000.00
SMT.L income_statement (annual, 2024-03-31) — Operating Revenue: 1377354000.00
SMT.L balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 1385868493.00
SMT.L cash_flow (annual, 2024-03-31) — Other Non Cash Items: 54981000.00
SMT.L balance_sheet (annual, 2024-03-31) — Payables: 227143000.00
SMT.L income_statement (annual, 2024-03-31) — Pretax Income: 1371720000.00
SMT.L cash_flow (annual, 2024-03-31) — Purchase Of Investment: -677577000.00
SMT.L balance_sheet (annual, 2024-03-31) — Receivables: 266379000.00
SMT.L cash_flow (annual, 2024-03-31) — Repayment Of Debt: -657625000.00
SMT.L cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -122056000.00
SMT.L cash_flow (annual, 2024-03-31) — Sale Of Investment: 1014781000.00
SMT.L income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 1095000.00
SMT.L income_statement (annual, 2024-03-31) — Selling General And Administration: 5634000.00
SMT.L balance_sheet (annual, 2024-03-31) — Share Issued: 1484780880.00
SMT.L balance_sheet (annual, 2024-03-31) — Stockholders Equity: 12629814000.00
SMT.L balance_sheet (annual, 2024-03-31) — Tangible Book Value: 12629814000.00
SMT.L income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 0.00
SMT.L income_statement (annual, 2024-03-31) — Tax Provision: 5757000.00
SMT.L income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.00
SMT.L cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -1685000.00
SMT.L balance_sheet (annual, 2024-03-31) — Total Assets: 14508672000.00
SMT.L balance_sheet (annual, 2024-03-31) — Total Capitalization: 14274270000.00
SMT.L balance_sheet (annual, 2024-03-31) — Total Debt: 1644456000.00
SMT.L balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 12629814000.00
SMT.L balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 1878858000.00
SMT.L balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 98912387.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Additional Paid In Capital: 947494000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Capital Stock: 74239000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 77685000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Federal Funds Sold: 77685000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Common Stock: 74239000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 11928583000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 13473177000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Invested Capital: 13518832000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 13473177000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Investments And Advances: 13473177000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 1590249000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Net Debt: 1512564000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 11928583000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 1285246434.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Payables: 38498000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Receivables: 12560000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Share Issued: 1484780880.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 11928583000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 11928583000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Total Assets: 13563422000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 13518832000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Total Debt: 1590249000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 11928583000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 1634839000.00
SMT.L balance_sheet (quarterly, 2024-09-30) — Treasury Shares Number: 199534446.00
SMT.L income_statement (annual, 2025-03-31) — +Operating Expense: 12653000.00
SMT.L income_statement (annual, 2025-03-31) — +Total Revenue: 1235966000.00
SMT.L balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 947494000.00
SMT.L balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 947494000.00
SMT.L income_statement (annual, 2025-03-31) — Basic Average Shares: 1287655573.00
SMT.L income_statement (annual, 2025-03-31) — Basic EPS: 0.95
SMT.L cash_flow (annual, 2025-03-31) — Beginning Cash Position: 123762000.00
SMT.L balance_sheet (annual, 2025-03-31) — Capital Stock: 60053000.00
SMT.L balance_sheet (quarterly, 2025-03-31) — Capital Stock: 60053000.00
SMT.L balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 9013000.00
SMT.L balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 9013000.00
SMT.L balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Federal Funds Sold: 9013000.00
SMT.L balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Federal Funds Sold: 9013000.00
SMT.L cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -55342000.00
SMT.L cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 3663000.00
SMT.L cash_flow (annual, 2025-03-31) — Change In Working Capital: 3663000.00
SMT.L cash_flow (annual, 2025-03-31) — Changes In Cash: -117234000.00
SMT.L balance_sheet (annual, 2025-03-31) — Common Stock: 60053000.00
SMT.L balance_sheet (quarterly, 2025-03-31) — Common Stock: 60053000.00
SMT.L cash_flow (annual, 2025-03-31) — Common Stock Dividend Paid: -55342000.00
SMT.L balance_sheet (annual, 2025-03-31) — Common Stock Equity: 12082465000.00
SMT.L balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 12082465000.00
SMT.L cash_flow (annual, 2025-03-31) — Common Stock Payments: -1747606000.00
SMT.L income_statement (annual, 2025-03-31) — Diluted Average Shares: 1287655573.00
SMT.L income_statement (annual, 2025-03-31) — Diluted EPS: 0.95
SMT.L income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 1217759000.00
SMT.L cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: 2485000.00